Pharming Group N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
25 jun 2008 - 14:10
Statutaire naam
Pharming Group N.V.
Titel
PHARMING ACQUIRES LICENSES TO KEY FIBRINOGEN PATENTS
Bericht
Leiden, The Netherlands, June 25, 2008. Biotech company Pharming Group NV (“Pharming” or “the Company”) (NYSE Euronext: PHARM) announced today that it has acquired an exclusive sub-license to key patents and technology on recombinant fibrinogen from GTC Biotherapeutics Inc (“GTC”). These rights enable Pharming to accelerate pharmaceutical development of recombinant human fibrinogen (rhFIB) and stimulate medical device development through its biomaterials program.
Pharming has obtained exclusive licenses on recombinant fibrinogen for all indications in various territories, including North America, Europe and Japan. The licenses are to recently issued patents owned by the American Red Cross, Virginia Tech Intellectual Properties Inc and the University of North Carolina on the production of recombinant fibrinogen in milk of transgenic animals which are licensed to GTC from ProGenetics, LLC. The license agreement includes an upfront payment to GTC of approximately € 350,000 (US$ 550,000) and a royalty on commercial sales of rhFIB. Pharming already owns several additional patents and licenses for recombinant fibrinogen and recombinant tissue sealant compositions. The acquisition of the license from GTC further broadens and strengthens Pharming’s position in this field.
Pharming has a development program for recombinant human fibrinogen as a replacement therapy for genetic and acquired deficiencies of fibrinogen. The existing market size for fibrinogen deficiencies is estimated to be over USD 500 million in the developed world. In addition to the deficiency market, rhFIB has the potential as a pharmaceutical product to address the significantly larger market of traumatic and surgical bleeding in excess of USD 1 billion. Current standard of care in the US for patients deficient in fibrinogen is the use of cryoprecipitate, which is composed mainly of plasma derived fibrinogen. In certain European countries, a partially purified plasma fibrinogen product is marketed.
Gerelateerde downloads
Datum laatste update: 09 augustus 2025